0001562180-21-001215.txt : 20210217 0001562180-21-001215.hdr.sgml : 20210217 20210217162531 ACCESSION NUMBER: 0001562180-21-001215 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210212 FILED AS OF DATE: 20210217 DATE AS OF CHANGE: 20210217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Christmas Patrick J. CENTRAL INDEX KEY: 0001521123 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37553 FILM NUMBER: 21645155 MAIL ADDRESS: STREET 1: C/O REGENXBIO INC. STREET 2: 9600 BLACKWELL ROAD, SUITE 210 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENXBIO Inc. CENTRAL INDEX KEY: 0001590877 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471851754 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9600 BLACKWELL ROAD STREET 2: SUITE 210 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 240-552-8181 MAIL ADDRESS: STREET 1: 9600 BLACKWELL ROAD STREET 2: SUITE 210 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: REGENXBIO, Inc. DATE OF NAME CHANGE: 20150116 FORMER COMPANY: FORMER CONFORMED NAME: ReGenX Biosciences, LLC DATE OF NAME CHANGE: 20131101 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2021-02-12 false 0001590877 REGENXBIO Inc. RGNX 0001521123 Christmas Patrick J. C/O REGENXBIO INC. 9600 BLACKWELL ROAD, SUITE 210 ROCKVILLE MD 20850 false true false false Chief Legal Officer Common Stock 2021-02-12 4 M false 4701.00 12.10 A 21073.00 D Common Stock 2021-02-12 4 S false 4701.00 49.08 D 16372.00 D Employee Stock Option (Right to Buy) 12.10 2021-02-12 4 M false 4701.00 0.00 D 2026-08-17 Common Stock 4701.00 6430.00 D This transaction was effected pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $49.00 to $49.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The previously granted option, representing a right to purchase a total of 125,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 18, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. /s/ Patrick J. Christmas 2021-02-17